Concepedia

Spencer E. McMinn

SE

Statistics

Publications

9

Citations

291

H-Index

9

Active since

2019

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Spencer E. McMinn is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

ORCID

Publications per year

2019–2024

9

Publications

9

Screening for generality in asymmetric catalysis

Corin Wagen, Spencer E. McMinn, Eugene E. Kwan et al. · Nature · 2022 · 116 citations · Full text

, , +12

Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors

Mitchell H. Keylor, Anmol Gulati, Solomon D. Kattar et al. · Journal of Medicinal Chemistry · 2021 · 42 citations · Full text

, , +17

Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy

Matthew J. Mitcheltree, Derun Li, Abdelghani Achab et al. · ACS Medicinal Chemistry Letters · 2020 · 30 citations · Full text

, , +15

Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 <i>H</i> -Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease

David A. Candito, Vladimir Simov, Anmol Gulati et al. · Journal of Medicinal Chemistry · 2022 · 24 citations · Full text

, , +15

Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors

Derun Li, Hongjun Zhang, Thomas W. Lyons et al. · ACS Medicinal Chemistry Letters · 2021 · 21 citations · Full text

, , +17

1–5 of 9